Price (delayed)
$19.98
Market cap
$1.88B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.14
Enterprise value
$1.87B
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue
There are no recent dividends present for FGEN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.